Tag: ENERGENESIS BIOMEDICAL CO.

Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational...

Energenesis Biomedical to Unveil Promising Parkinson’s Disease Therapy, ENERGI-F705PD, at BIO International 2025

TAIPEI, June 11, 2025 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsENERGENESIS BIOMEDICAL CO.

ABCmouse® Partners with Southwest Airlines to Bring Learning to the Skies

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

DeRUCCI Group Opens First AI Smart Sleep Flagship Experience Store in Vietnam

Tag: ENERGENESIS BIOMEDICAL CO.

Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease

Energenesis Biomedical to Unveil Promising Parkinson’s Disease Therapy, ENERGI-F705PD, at BIO International 2025

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us